AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results for AZN
4,244.66
+128.66 (3.13%)
Dec 9 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,134.50 - 4,436.74
52 week 3,680.00 - 5,505.00
Open 4,149.50
Vol / Avg. 5.52M/3.06M
Mkt cap 53.93B*
P/E 27.50
Div/yield 68.70*
EPS 1.54*
Shares 1.27B
Beta     -
Inst. own     -
*GBP
Feb 2, 2017
Full Year 2016 AstraZeneca PLC Earnings Release - 7:00AM GMT - Add to calendar
Dec 15, 2016
AstraZeneca PLC Second Year-End Late-Stage Pipeline Investor Science Conference Call - 3:30PM GMT - Add to calendar
Dec 5, 2016
AstraZeneca PLC at Berenberg European Conference
Dec 1, 2016
AstraZeneca PLC at Deutsche Bank dbAccess Pharmaceutical and Healthcare Corporate Day
Nov 24, 2016
AstraZeneca PLC Investor Roadshow - London
Nov 17, 2016
AstraZeneca PLC Investor Roadshow - US West Coast
Nov 17, 2016
AstraZeneca PLC Investor Roadshow- Basel
Nov 16, 2016
AstraZeneca PLC Investor Roadshow- Geneva
Nov 15, 2016
AstraZeneca PLC at Stifel Healthcare Conference
Nov 14, 2016
AstraZeneca PLC Investor Roadshow- US East Coast
  

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 17.46% 11.44%
Operating margin 18.04% 16.65%
EBITD margin - 34.83%
Return on average assets 6.25% 4.76%
Return on average equity 30.58% 14.82%
Employees 61,500 -
CDP Score - 97 B

Address

- Legal Department, 2 Kingdom Street
LONDON, W2 6BD
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Officers and directors

Pascal Soriot Executive Director and Chief Executive Officer
Age: 57
Marc Dunoyer Executive Director, Chief Financial Officer
Age: 63
Fiona Cicconi Executive Vice-President, Human Resources
Sean Bohen M.D., Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Pam P. Cheng Executive Vice President - Operations and Information Technology
Age: 45
Ruud Dobber Executive Vice President, Europe
Paul Hudson President, AstraZeneca, US and Executive Vice-President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, International
Luke Miels Executive Vice-President, Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs